AstraZeneca Stock Gains 5% as China Approves Key Cancer Drug

Edgen Stock

·Mar 27 2026, 13:58

Share to

Share to

Copy link

Key Takeaways

AstraZeneca's stock gained after securing a landmark approval in China for its cancer therapy Enhertu, co-developed with Daiichi Sankyo. This approval, a global first for this specific breast cancer treatment, unlocks a major new revenue stream and reinforces the drug's blockbuster potential, further supported by recent regulatory wins in Japan.

China's drug administration approved Enhertu on March 27, causing a 5% increase in AstraZeneca's US stock price.
The approval is a global first for neoadjuvant treatment of early-stage breast cancer, positioning China as a key launch market for innovative drugs.
The news builds on Enhertu's recent regulatory successes in Japan for treating various solid tumors and gastric cancer, signaling strong global momentum for the therapy.

China Approval Lifts AstraZeneca Stock 5%

AstraZeneca's US-listed shares climbed 5% on March 27 after the company announced a significant regulatory victory in China. The country's National Medical Products Administration granted approval for Enhertu (trastuzumab deruxtecan), an advanced cancer therapy co-developed with Japan's Daiichi Sankyo. This decision provides AstraZeneca access to the vast Chinese market for one of its key oncology assets, driving immediate investor confidence.

Enhertu Secures World-First Indication in China

This approval marks a strategic milestone, as China is the first country globally to approve Enhertu as a neoadjuvant (pre-operative) treatment for patients with early-stage breast cancer. The move highlights China's accelerating drug approval reforms and its growing role as a crucial primary market for global pharmaceutical innovations. The therapy is designed to reduce the risk of disease recurrence and improve the potential for a cure.

The approval of this innovative injection offers a new treatment option and hope for clinical cure to more early-stage breast cancer patients in the country.

— Wu Jiong, Party secretary of Fudan University Shanghai Cancer Center.

Global Momentum Builds with Japanese Regulatory Wins

The Chinese market entry is part of a broader pattern of success for Enhertu, which has secured multiple approvals globally. In Japan, the drug was recently approved as the first tumor-agnostic HER2-directed medicine, its sixth approved indication in the country. Clinical data from the HERALD trial supporting this showed a confirmed objective response rate (ORR) of 56.5% across a range of solid cancers. Separately, Japanese regulators expanded Enhertu's use for second-line gastric cancer after a Phase 3 trial demonstrated a 30% reduction in the risk of death versus standard care. These consistent wins validate Enhertu's efficacy and underpin its importance as a major growth driver for AstraZeneca.